Terumo (TRUMY) Expected to Announce Quarterly Earnings on Thursday

Terumo (OTCMKTS:TRUMY) is anticipated to post its results after the market closes on Thursday, November 12th. Analysts expect Terumo to post earnings of ($0.0085) per share and revenue of $1.94 billion for the quarter.

Terumo (OTCMKTS:TRUMY) last posted its quarterly earnings data on Friday, August 7th. The company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.17 by $0.13. The business had revenue of $1.97 billion for the quarter, compared to analysts’ expectations of $1.84 billion. Terumo had a net margin of 13.83% and a return on equity of 10.44%. On average, analysts expect Terumo to post $0.86 EPS for the current fiscal year and $0.80 EPS for the next fiscal year.

Terumo Price Performance

Terumo stock opened at $15.07 on Thursday. Terumo has a 12-month low of $12.08 and a 12-month high of $16.99. The company has a current ratio of 2.19, a quick ratio of 1.37 and a debt-to-equity ratio of 0.13. The firm has a 50-day moving average price of $14.82 and a 200-day moving average price of $14.02. The firm has a market capitalization of $22.24 billion, a PE ratio of 21.23 and a beta of 0.82.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Nomura raised shares of Terumo from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 30th. Zacks Research upgraded Terumo from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 13th. Two analysts have rated the stock with a Strong Buy rating. According to data from MarketBeat, Terumo presently has a consensus rating of “Strong Buy”.

Terumo Company Profile

Terumo Corporation is a Japan-based medical technology company that develops, manufactures and sells medical devices and healthcare products. Its offerings support hospitals, physicians and other healthcare providers across areas including cardiovascular care, interventional procedures, blood management, cell and gene therapies, and general medical care.

The company’s products include catheters, guidewires, stents and other devices used in cardiovascular and endovascular procedures, as well as blood bags, apheresis systems, cell-processing technologies, infusion and injection products, and hospital equipment.